NFSG Corp Buys 10,060 Shares of Tempus AI, Inc. $TEM

NFSG Corp raised its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 953.6% during the first quarter, Holdings Channel reports. The firm owned 11,115 shares of the company’s stock after buying an additional 10,060 shares during the quarter. NFSG Corp’s holdings in Tempus AI were worth $503,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Royal Bank of Canada lifted its position in shares of Tempus AI by 201.2% in the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after purchasing an additional 17,359 shares during the period. Rhumbline Advisers bought a new stake in shares of Tempus AI during the 1st quarter valued at about $116,000. Prudential Financial Inc. purchased a new position in shares of Tempus AI during the second quarter valued at about $276,000. Russell Investments Group Ltd. increased its position in shares of Tempus AI by 21.3% during the second quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock valued at $415,000 after buying an additional 1,146 shares during the period. Finally, Invesco Ltd. raised its stake in Tempus AI by 2,926.6% in the second quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after buying an additional 204,629 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors.

Insider Transactions at Tempus AI

In related news, CFO James William Rogers sold 11,529 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the transaction, the chief financial officer owned 114,866 shares of the company’s stock, valued at $6,317,630. This trade represents a 9.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction on Monday, June 29th. The shares were sold at an average price of $57.48, for a total value of $9,556,050.00. Following the transaction, the chief executive officer owned 8,775,283 shares of the company’s stock, valued at $504,403,266.84. The trade was a 1.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 616,043 shares of company stock worth $31,748,593. Company insiders own 24.26% of the company’s stock.

Tempus AI Trading Down 2.4%

Shares of NASDAQ TEM opened at $57.25 on Thursday. Tempus AI, Inc. has a 1 year low of $41.73 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The firm has a 50-day moving average of $51.46 and a 200 day moving average of $54.12. The stock has a market cap of $10.28 billion, a P/E ratio of -33.28 and a beta of 3.46.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. During the same quarter in the prior year, the company earned ($0.24) earnings per share. The business’s revenue was up 36.1% compared to the same quarter last year. As a group, sell-side analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on TEM shares. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. HC Wainwright decreased their target price on Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Freedom Capital upgraded Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Finally, Guggenheim reduced their price target on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $68.54.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.